➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Last Updated: October 26, 2020

DrugPatentWatch Database Preview

Patent: 4,582,787

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 4,582,787
Title: Method of testing a patient for a predisposition to lung cancer, certain other cancers, neurofibromatosis and certain other hereditary disorders
Abstract:A method is disclosed for testing a patient to determine a predisposition to lung cancer and neurofibromatosis. The method comprises the steps of carrying out a biopsy on each patient of a first group of patients known to have a cancer or a cancer with a known hereditary component such as neurofibromatosis, the biopsy including the removal of a skin sample from each patient. The removed skin samples are prepared for in vitro testing thereof, initially to prove contamination is not present. In vitro testing is carried out to determine whether viral transformation of cultures established from the skin samples exists. Portions of Kirsten murine sarcoma virus are prepared and added to the uncontaminated cultured skin cells. The skin cells treated with the Kirsten murine sarcoma virus are incubated and a viral assay is performed to determine which skin cultures have been transformed due to the treatment with Kirsten murine sarcoma virus. The foregoing steps are performed relative to a second group of cancer and neurofibromatosis-free patients. An index is composed from the results of the assays performed on the first and second groups of patients. The foregoing steps are repeated relative to a subsequent patient, the predisposition to lung cancer and/or neurofibromatosis of which is unknown and a comparison of the results obtained from the assay relative to the subsequent patient is compared with the index to determine whether a predisposition to lung cancer and neurofibromatosis exists relative to the subsequent patient.
Inventor(s): Frankel; Jack W. (Treasure Island, FL)
Application Number:06/454,880
Patent Claims:see list of patent claims

Details for Patent 4,582,787

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew SANTYL collagenase OINTMENT;TOPICAL 101995 001 1965-06-04   Start Trial 2039-03-29 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.